SKYE — Skye Bioscience Share News
0.000.00%
Last trade - 00:00Skye Bioscience rises on launch of obesity drug trial
Skye Bioscience Inc reports results for the quarter ended in June - Earnings Summary
Skye Bioscience Inc expected to post a loss of 19 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Biomea Fusion, Enphase Energy, Perion Network
U.S. STOCKS ON THE MOVE-FuelCell Energy, Copper miners , Apollo Global Management
U.S. STOCKS ON THE MOVE-GameStop, gold miners, Honeywell
U.S. STOCKS ON THE MOVE-PG&E, ICC Holdings, Krispy Kreme
U.S. STOCKS ON THE MOVE-Walmart, GameStop, Moderna
Skye Bioscience to stop eye disease drug development after failing mid-stage study (updated)
Skye Bioscience slumps on scrapping eye disease treatment development
Skye Bioscience to discontinue development of eye disease treatment
Brief: Skye Bioscience Files For Mixed Shelf Of Up To $300 Mln
Skye Bioscience Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Skye Bioscience Uplists to The Nasdaq Global Market
Brief: Skye Bioscience Completes Enrollment of Phase 2a Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
Brief: Shareholders Oppose Plan Of Arrangement Between Emerald Health Therapeutics And Skye Biosciences Inc
Brief: Skye Bioscience Appoints Praveen Tyle To Board Of Directors
Brief: Emerald Bioscience Reports Publication In Peer-Reviewed Journal
Brief: Emerald Bioscience Announces Notice Of Allowance From United States Patent Office For Proprietary Analog Of Cannabidiol